Antileukemic Natural Product Induced Both Apoptotic and Pyroptotic Programmed Cell Death and Differentiation Effect

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Acute myeloid leukemia (AML) presents significant treatment challenges due to poor chemotherapy response and high relapse rates.
• Novel therapeutic strategies are crucial to address unmet needs in AML management.

Purpose of the Study:

• To investigate the antileukemic effects of ardisianone, a plant-derived alkyl benzoquinone.
• To elucidate the mechanisms underlying ardisianone's action on leukemic cells.

Main Methods:

• Western blotting to analyze apoptosis-related protein expression (e.g., TNFR2, caspases, IAPs).
• Transmission electron microscopy and Western blot analysis for pyroptosis markers (e.g., gasdermin D, caspase-1).
• Flow cytometry (CD11b, CD68) and Wright-Giemsa staining to assess cell differentiation.

Main Results:

• Ardisianone induced apoptosis by upregulating death receptors and downregulating inhibitor of apoptosis proteins (IAPs), activating caspase-8 and -3.
• Ardisianone triggered pyroptosis, evidenced by gasdermin D cleavage and detection of key pyroptosis markers.
• Ardisianone promoted differentiation of surviving leukemic cells into monocyte/macrophage-like cells, indicated by CD11b and CD68 expression.

Conclusions:

• Ardisianone effectively induces apoptosis and pyroptosis in AML cells via caspase pathway activation and IAP downregulation.
• Ardisianone demonstrates potential as a therapeutic agent by inducing programmed cell death and promoting leukemic cell differentiation.